Solarase data

HYALF announced preliminary Phase III results in 189 patients. After 60 days of treatment with 0.5 g of Solarase, the number of lesions decreased in treated patients compared to placebo (p=0.002).

Another pivotal trial is expected to end in the third quarter of 1996, with filing for marketing approval planned by the end of the year. ...